ATR

AptarGroup

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Medical Instruments & Supplies

Exchange

NYSE

County of HQ

United States

Next Earnings Date

04/30/26

Business Summary

AptarGroup designs and manufactures dispensing systems and medical components that sit inside everyday healthcare and pharmaceutical products, making it a picks-and-shovels supplier rather than a branded end-product company. Its cash generation is driven by recurring demand for drug delivery systems, closures, and precision components that are embedded in customer supply chains. Switching costs and regulatory validation cycles create stickiness, as customers are reluctant to redesign packaging and delivery systems once approved. The moat is operational and relationship-based: consistent manufacturing quality, scale efficiencies, and integration into customer production lines support durable revenue streams and steady free cash characteristics.

VALUATION

P/E

22.3

Market Cap ($M USD)

$8,386

Forward P/E

20.7

PEG

3.5

PRICE TO SALES

2.3

PRICE TO BOOK

3.1

EV / EBITDA

11.4

5-Year Average P/E

DIVIDEND

Yield

1.40%

Annual Payout

$1.86

Payout Ratio

30.70%

Consecutive Years of Dividend Growth

10+

5-Year Dividend Growth Rate

5.90%

Financial Health & Profitability

Earnings Per Share

$5.97

Next Year EPS Growth Estimate

$6.37

Next Year Revenue Growth Estimate

5.00%

Return on Equity (ROE)

14.70%

Operating Margin

13.50%

Debt-to-Equity

0.6

Piotroski F-Score

5

Altman Z-Score

3.9

Return on Invested Capital (ROIC)

11.00%%

Current Ratio

1.6

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 22.3x earnings and 20.7x forward earnings, ATR is priced as a stable compounder rather than a bargain, yet the 3.9 Altman Z-Score signals strong balance sheet safety and low bankruptcy risk. The spread between the current P/E and forward P/E implies modest earnings expansion, but a PEG of 3.5 suggests the market is paying a premium relative to growth expectations. With a 14.70% operating margin and 11.00% ROIC, profitability is respectable but not elite, while a 5.00% ROE indicates capital efficiency is merely average. This is not deep value, but it is financially sound—arguably fairly valued with limited margin of safety unless execution materially improves.

AI Exposure / Tech Reliance

As a Medical Instruments & Supplies company within Healthcare, ATR operates in a segment that benefits from automation, precision manufacturing, and data-integrated device ecosystems. AI-driven design optimization and manufacturing efficiency could support margin stability, especially with a 14.70% operating margin already in place. However, it is not a pure AI levered play; its tech resilience is incremental rather than transformative.

The Bull Case

A GARP investor can justify ownership based on financial stability and disciplined capital deployment. The company generates an 11.00% ROIC against a modest 13.50% Debt/Equity ratio, suggesting returns are not being artificially inflated by leverage. A Piotroski F-Score of 5 indicates average but stable operational health, while a 1.6 current ratio reinforces liquidity comfort. The 3.9 Altman Z-Score materially reduces balance sheet risk, and 5.90% short interest is not elevated enough to signal systemic skepticism. Combined with a 0.6 TTM yield and a dividend profile supported by a 10+ five-year average growth rate, this is a steady institutional compounder suited for conservative capital rather than speculative upside.

The Bear Case

The valuation is the primary vulnerability. A PEG of 3.5 is expensive relative to growth, and a 22.3 P/E for a business generating only 5.00% ROE is not compelling. Operating margins of 14.70% are solid but not dominant within Healthcare, limiting pricing power narratives. Short interest at 5.90% hints at some skepticism, and with Sales Growth Next Year listed at $6.37 alongside EPS Next Year of $5.97, expectations appear tightly priced into the 20.7 forward multiple. If growth underdelivers even modestly, multiple compression becomes the central risk.

Market Sentiment & Smart Money

Short Interest %

2.30%

Analyst Consensus

2.11

Average Analyst Price Target

$163.57

Institutional Ownership %

96.30%

1-Year Beta

0.68

Insider Buying % (6 Mo)

0.80%%

Distance to 52-Week High

80.10%%

Distance to 52-Week Low

127.40%%